This is highly relevant, as JAK2-driven PV models demonstrated profound metabolic dysregulation, including hypoglycemia and cachexia, supporting the concept that these malignancies exhibit metabolic alterations that may be therapeutically targeted [66]. This evidence concerns the gene JAK2 and acquired polycythemia vera.